DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)

SHA:603233 Revenue

DaShenLin Pharmaceutical Group had revenue of 6.97B CNY in the quarter ending March 31, 2026, with 0.25% growth. This brings the company's revenue in the last twelve months to 27.52B, up 3.07% year-over-year. In the year 2025, DaShenLin Pharmaceutical Group had annual revenue of 27.50B with 3.80% growth.

• Revenue (ttm): 27.52B
• Revenue Growth: +3.07%
• P/S Ratio: 0.68
• Revenue / Employee: 668.91K
• Employees: 41,141
• Market Cap: 18.79B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	27.50B	1.01B	3.80%
Dec 31, 2024	26.50B	1.97B	8.01%
Dec 31, 2023	24.53B	3.28B	15.45%
Dec 31, 2022	21.25B	4.49B	26.78%
Dec 31, 2021	16.76B	2.18B	14.92%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 26, 2026

Data Sources Report a data error